Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)

By sjmartinez • May 14, 2024

Razavi AC, Richardson LC, Coronado F, Dzaye O, Bhatia HS, Mehta A, Quyyumi AA, Vaccarino V, Budoff MJ, Nasir K, Tsimikas S, Whelton SP, Blaha MJ, Blumenthal RS, Sperling LS. Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a). Am J Prev Cardiol. 2024 Apr 27;18:100674. doi: 10.1016/j.ajpc.2024.100674. PMID: 38741703; PMCID: PMC11090055.

Tags: Aspirin, Cardiology/Epi, cardiovascular disease, Harbor UCLA, lipoprotein(a), NHANES, Publications

Late-in-life treadmill-training mitigates gut microbiome imbalances and cardiovascular disease risk in mice

Cho JM, Park SK, Satheesh Babu AK, Mookherjee S, Hansen M, Petersen C, Zhong Y, Jalili T, Robeson MS, Whankade UD, Anandh Babu PV, Symons[...]

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira[...]

New strategies for valve replacement and interventional options in adults with congenital heart disease: new insights from Euro-ACHD 2025

Butera G, Chessa M, Gaio G, Kempny A, Uebing A, Michielon G, Aboulhosn J, Giamberti A, Hoschtitzky A, d'Udekem Y. New strategies for valve replacement[...]